With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1083224-23-0,5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.,1083224-23-0
[0301] To a solution of 5 -(2, 4-difluorophenyl)isoxazole-3 -carboxylic acid (100 mg, 0.44 mmol, 1 equiv) in DMF (1 mL), were added HATU (185 mg, 0.48 mmol, 1.1 equiv). The mixture was treated drop wise with DIPEA (183 mg, 1.42 mmol, 3.2 equiv). After stirring at RT for 15 minutes, the mixture was treated drop wise with a solution of the l-(2,4- bis(trifluoromethyl)benzyl)-lH-pyrazol-4-amine (137 mg, 0.44 mmol, 1 equiv) in DMF (1 mL). The reaction mixture was kept under stirring for 24 hrs at RT. Product formation was confirmed with TLC & LCMS and reaction mixture was diluted EtOAc (50 mL) & washed with water (50 mL X 2). Organic layer dried over Na2S04 & concentrated under reduced pressure to obtain crude which was further purified by flash column chromatography to obtain pure product N-(l-(2,4-bis(trifluoromethyl)benzyl)-lH-pyrazol-4-yl)-5-(2,4- difluorophenyl)isoxazole-3-carboxamide. (36 mg, 15.7% as off white solid) ‘fl NMR (400 MHz, DMSO-c 6) d 11.16 (s, 1H), 8.33 (s, 1H), 8.10 (q, J= 8.3 Hz, 3H), 7.78 (s, 1H), 7.6l(t, J= 10.9 Hz, 1H), 7.35 (dd, J= 10.1, 7.7 Hz, 1H), 7.26 (d, J= 2.9 Hz, 1H), 7.06 (d, J= 8.1Hz, lH),5.67 (s, 2H).
The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; PRAXIS BIOTECH LLC; ALFARO, Jennifer; BELMAR, Sebastian; NUNEZ VASQUEZ, Gonzalo Esteban; PUJALA, Brahmam; SATHE, Balaji Dashrath; BERNALES, Sebastian; CHAKRAVARTY, Sarvajit; THAKRAL, Pooja; PATIDAR, Rajesh Kumar; (344 pag.)WO2019/195810; (2019); A2;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem